---
title: "Formula-509: Postprostatectomy Salvage Radiotherapy With Abiraterone and Apalutamide"
id: "european-urology-29-formula-509-a-multicenter-randomized-trial-of-postprostatectomy-salvage-radiotherapy-and-6-months-of-a-gnrh-agonist-with-either-bicalutamide-or-abiraterone-acetate-plus-prednisone-and-apalutamide"
canonical_url: "https://medichelpline.com/clinical-feed/european-urology-29-formula-509-a-multicenter-randomized-trial-of-postprostatectomy-salvage-radiotherapy-and-6-months-of-a-gnrh-agonist-with-either-bicalutamide-or-abiraterone-acetate-plus-prednisone-and-apalutamide"
content_type: "clinical_feed_article"
specialty: "Urology"
source_name: "European Urology"
source_url: "https://www.europeanurology.com/article/S0302-2838(25)04854-7/fulltext?rss=yes"
published_at: "2026-02-10T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Formula-509: Postprostatectomy Salvage Radiotherapy With Abiraterone and Apalutamide
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/european-urology-29-formula-509-a-multicenter-randomized-trial-of-postprostatectomy-salvage-radiotherapy-and-6-months-of-a-gnrh-agonist-with-either-bicalutamide-or-abiraterone-acetate-plus-prednisone-and-apalutamide
- **Specialty:** [Urology](https://medichelpline.com/clinical-feed/urology.md)
- **Primary Source:** European Urology
- **Source URL:** [Original Journal Publication](https://www.europeanurology.com/article/S0302-2838(25)04854-7/fulltext?rss=yes)
- **Published At:** 2026-02-10T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
For patients receiving salvage radiation therapy and 6 mo of androgen deprivation therapy for prostate cancer recurrence after radical prostatectomy, addition of abiraterone + apalutamide improved outcomes for patients with prostate-specific antigen >0.5 ng/ml.
## Clinical Analysis & Structured Key Points
European Urology published a clinical update in Research Highlights on 10 Feb 2026. The item focuses on FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. Review the original article for the full source wording and details.
## Related Clinical Research

- [Probable CLIPPERS in a Patient with Cutaneous T‑Cell Lymphoma Remission: 5‑Year Follow‑Up (Report](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-case-report-probable-clippers-in-a-patient-with-cutaneous-t-cell-lymphoma-in.md)
- [Chart-Derived Lee Score, Upfront ARSI Use, and Competing Mortality in Metastatic Hormone-Sensitive](https://medichelpline.com/clinical-feed/pubmed-42533722.md) (DOI: 10.1111/ggi.70720)
- [Apoptosis-Related Genes WNT1 and S100A8 Link Inflammatory Bowel Disease and Osteoporosis](https://medichelpline.com/clinical-feed/plos-one-1-apoptosis-related-genes-bridge-inflammatory-bowel-disease-and-osteoporosis-a.md)
- [Infections and Hypogammaglobulinemia with Low‑Dose Rituximab in Myasthenia Gravis — Full Text Not](https://medichelpline.com/clinical-feed/frontiers-in-immunology-18-infections-and-hypogammaglobulinemia-in-myasthenia-gravis-patients-receiving.md)
- [Evaluating Focal Therapy for Localized Prostate Cancer: A Shift in Perspectives?](https://medichelpline.com/clinical-feed/stat-news-0-focal-therapy-for-localized-prostate-cancer-has-divided-physicians-will-new.md)

## Navigation
- [← Back to Urology Feed](https://medichelpline.com/clinical-feed/urology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.